Daily Newsletter

30 October 2023

Daily Newsletter

30 October 2023

UK allocates £100m for AI-powered new drug development 

UK Prime Minister Rishi Sunak has announced new investment in the life sciences and healthcare fields.

Vishnu Priyan October 30 2023

The UK Government is making a £100m ($121.14m) investment to leverage artificial intelligence (AI) to develop new, transformational therapies for previously incurable ailments.

Prime Minister Rishi Sunak announced the AI Life Sciences Accelerator Mission, a new initiative in life sciences and healthcare. 

The investment will be used in areas where rapid AI deployment has the potential to create transformational breakthroughs. 

The mission will leverage the UK's secure health data using AI to address eight tasks, including developing cancer therapies and dementia treatment.

The project will detect individuals at risk of ailments such as dementia and related conditions and they will join trials for developing new therapies.

This approach will collect crucial data on the working mechanisms of such therapies. 

The latest grant will facilitate government investment in areas with increased clinical requirements in 2024 to 2025. 

The government also intends to deploy AI in clinical settings to enhance health outcomes. 

By establishing a robust data infrastructure, it plans to enhance mental health research in the next five years.

Sunak stated: “AI can help us solve some of the greatest social challenges of our time. AI could help find novel dementia treatments or develop vaccines for cancer.

“That’s why today we’re investing a further £100m to accelerate the use of AI on the most transformational breakthroughs in treatments for previously incurable diseases.”

Analyzing the key M&A trends in the Contract Manufacturing industry

Despite challenging business conditions in 2021 and 2022, large CMOs were still involved in acquisitions to enhance their capabilities or scale of production. Catalent and Recipharm were particularly active in acquiring companies during this period, and these acquisitions had a focus on advanced biologic capabilities related to cell and gene therapies. CMOs are increasingly targeting companies with sophisticated (biologic and specialized) capabilities to manufacture modern drugs and seek high-value contracts.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close